Debt-to-equity in % of HCW Biologics Inc. from Q3 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
HCW Biologics Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2025.
  • HCW Biologics Inc. Debt-to-equity for the quarter ending September 30, 2025 was -734 %, a 141% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

HCW Biologics Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -734 -2.53K -141% Sep 30, 2025
Q2 2025 -542 -747 -364% Jun 30, 2025
Q1 2025 -448 -527 -663% Mar 31, 2025
Q4 2024 -898 -947 -1919% Dec 31, 2024
Q3 2024 1.79K +1.76K +5015% Sep 30, 2024
Q2 2024 205 +177 +624% Jun 30, 2024
Q1 2024 79.6 +60.4 +316% Mar 31, 2024
Q4 2023 49.3 +37.4 +313% Dec 31, 2023
Q3 2023 35.1 +27.7 +377% Sep 30, 2023
Q2 2023 28.3 Jun 30, 2023
Q1 2023 19.1 Mar 31, 2023
Q4 2022 12 Dec 31, 2022
Q3 2022 7.35 Sep 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.